Re­gen­eron/Sanofi PD-1 tri­al halt­ed for sig­nif­i­cant ef­fi­ca­cy; Avadel soars on pos­i­tive nar­colep­sy da­ta

→ It’s a good news, bad news day for Sanofi and Re­gen­eron. On the same morn­ing their joint Kevzara tri­al pro­duced dis­ap­point­ing re­sults for Covid-19, the biotech-phar­ma part­ners an­nounced that a Phase III tri­al test­ing their im­munother­a­py Lib­tayo on non-small cell lung can­cer had been stopped ear­ly af­ter hav­ing shown clear ben­e­fit in im­prov­ing over­all sur­vival. The PD-1 in­hibitor re­duced the risk of death by 32% in first-line pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER